Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
Avalyn Pharma
Apr 30, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
CareDx has acquired Naveris, a diagnostics imaging business in California, for up to $260 million. Naveris provides precision oncology diagnostics imaging services that support clinical decision-making and patient management in oncology care. CareDx acquisitions aim to expand its precision oncology platform by integrating Naveris capabilities into its existing diagnostic offerings. The strategic acquisition is structured as a platform acquisition within healthcare M&A, with deal value over $100 million and total consideration up to $260 million. The announced transaction is expected to close subject to customary conditions and approvals.
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Avalyn Pharma
Apr 30, 2026
Avalyn Pharma
Apr 30, 2026
Parexel→Vitrana
Apr 29, 2026
Chiesi Group→KalVista Pharmaceuticals
Apr 29, 2026
CareDx→Naveris
Apr 29, 2026